Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses

Alessaadro Cignetti, Antonella Vallario, Ilaria Roato, Paola Circosta, Bernardino Allione, Laura Casorzo, Paolo Ghia, Federico Caligaris-Cappio

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Primary acute myeloid leukemia cells can be induced to differentiate into dendritic cells (DC). In the presence of GM-CSF, TNF-α, and/or IL-4, leukemia-derived DC are obtained that display features of immature DC (i-DC). The aim of this study was to determine whether i-DC of leukemic origin could be further differentiated into mature DC (m-DC) and to evaluate the possibility that leukemic m-DC could be effective in vivo as a tumor vaccine. Using CD40L as maturating agent, we show that leukemic i-DC can differentiate into cells that fulfill the phenotypic criteria of m-DC and, compared with normal counterparts, are functionally competent in vitro in terms of: 1) production of cytokines that support T cell activation and proliferation and drive Th1 polarization; 2) generation of autologous CD8+ CTLs and CD4+ T cells that are MHC-restricted and leukemia-specific; 3) migration from tissues to lymph nodes; 4) amplification of Ag presentation by monocyte attraction; 5) attraction of naive/resting and activated T cells. Irradiation of leukemic i-DC after CD40L stimulation did not affect their differentiating and functional capacity. Our data indicate that acute myeloid leukemia cells can fully differentiate into functionally competent m-DC and lay the ground for testing their efficacy as a tumor vaccine.

Original languageEnglish
Pages (from-to)2855-2865
Number of pages11
JournalJournal of Immunology
Volume173
Issue number4
Publication statusPublished - Aug 15 2004

Fingerprint

Dendritic Cells
Leukemia
T-Lymphocytes
CD40 Ligand
Cancer Vaccines
Myeloid Cells
Acute Myeloid Leukemia
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-4
Monocytes
Lymph Nodes
Cell Proliferation
Cytokines

ASJC Scopus subject areas

  • Immunology

Cite this

Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. / Cignetti, Alessaadro; Vallario, Antonella; Roato, Ilaria; Circosta, Paola; Allione, Bernardino; Casorzo, Laura; Ghia, Paolo; Caligaris-Cappio, Federico.

In: Journal of Immunology, Vol. 173, No. 4, 15.08.2004, p. 2855-2865.

Research output: Contribution to journalArticle

Cignetti, Alessaadro ; Vallario, Antonella ; Roato, Ilaria ; Circosta, Paola ; Allione, Bernardino ; Casorzo, Laura ; Ghia, Paolo ; Caligaris-Cappio, Federico. / Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. In: Journal of Immunology. 2004 ; Vol. 173, No. 4. pp. 2855-2865.
@article{3f076ab9332e403bbd5b588a69543d87,
title = "Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses",
abstract = "Primary acute myeloid leukemia cells can be induced to differentiate into dendritic cells (DC). In the presence of GM-CSF, TNF-α, and/or IL-4, leukemia-derived DC are obtained that display features of immature DC (i-DC). The aim of this study was to determine whether i-DC of leukemic origin could be further differentiated into mature DC (m-DC) and to evaluate the possibility that leukemic m-DC could be effective in vivo as a tumor vaccine. Using CD40L as maturating agent, we show that leukemic i-DC can differentiate into cells that fulfill the phenotypic criteria of m-DC and, compared with normal counterparts, are functionally competent in vitro in terms of: 1) production of cytokines that support T cell activation and proliferation and drive Th1 polarization; 2) generation of autologous CD8+ CTLs and CD4+ T cells that are MHC-restricted and leukemia-specific; 3) migration from tissues to lymph nodes; 4) amplification of Ag presentation by monocyte attraction; 5) attraction of naive/resting and activated T cells. Irradiation of leukemic i-DC after CD40L stimulation did not affect their differentiating and functional capacity. Our data indicate that acute myeloid leukemia cells can fully differentiate into functionally competent m-DC and lay the ground for testing their efficacy as a tumor vaccine.",
author = "Alessaadro Cignetti and Antonella Vallario and Ilaria Roato and Paola Circosta and Bernardino Allione and Laura Casorzo and Paolo Ghia and Federico Caligaris-Cappio",
year = "2004",
month = "8",
day = "15",
language = "English",
volume = "173",
pages = "2855--2865",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses

AU - Cignetti, Alessaadro

AU - Vallario, Antonella

AU - Roato, Ilaria

AU - Circosta, Paola

AU - Allione, Bernardino

AU - Casorzo, Laura

AU - Ghia, Paolo

AU - Caligaris-Cappio, Federico

PY - 2004/8/15

Y1 - 2004/8/15

N2 - Primary acute myeloid leukemia cells can be induced to differentiate into dendritic cells (DC). In the presence of GM-CSF, TNF-α, and/or IL-4, leukemia-derived DC are obtained that display features of immature DC (i-DC). The aim of this study was to determine whether i-DC of leukemic origin could be further differentiated into mature DC (m-DC) and to evaluate the possibility that leukemic m-DC could be effective in vivo as a tumor vaccine. Using CD40L as maturating agent, we show that leukemic i-DC can differentiate into cells that fulfill the phenotypic criteria of m-DC and, compared with normal counterparts, are functionally competent in vitro in terms of: 1) production of cytokines that support T cell activation and proliferation and drive Th1 polarization; 2) generation of autologous CD8+ CTLs and CD4+ T cells that are MHC-restricted and leukemia-specific; 3) migration from tissues to lymph nodes; 4) amplification of Ag presentation by monocyte attraction; 5) attraction of naive/resting and activated T cells. Irradiation of leukemic i-DC after CD40L stimulation did not affect their differentiating and functional capacity. Our data indicate that acute myeloid leukemia cells can fully differentiate into functionally competent m-DC and lay the ground for testing their efficacy as a tumor vaccine.

AB - Primary acute myeloid leukemia cells can be induced to differentiate into dendritic cells (DC). In the presence of GM-CSF, TNF-α, and/or IL-4, leukemia-derived DC are obtained that display features of immature DC (i-DC). The aim of this study was to determine whether i-DC of leukemic origin could be further differentiated into mature DC (m-DC) and to evaluate the possibility that leukemic m-DC could be effective in vivo as a tumor vaccine. Using CD40L as maturating agent, we show that leukemic i-DC can differentiate into cells that fulfill the phenotypic criteria of m-DC and, compared with normal counterparts, are functionally competent in vitro in terms of: 1) production of cytokines that support T cell activation and proliferation and drive Th1 polarization; 2) generation of autologous CD8+ CTLs and CD4+ T cells that are MHC-restricted and leukemia-specific; 3) migration from tissues to lymph nodes; 4) amplification of Ag presentation by monocyte attraction; 5) attraction of naive/resting and activated T cells. Irradiation of leukemic i-DC after CD40L stimulation did not affect their differentiating and functional capacity. Our data indicate that acute myeloid leukemia cells can fully differentiate into functionally competent m-DC and lay the ground for testing their efficacy as a tumor vaccine.

UR - http://www.scopus.com/inward/record.url?scp=4043126718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043126718&partnerID=8YFLogxK

M3 - Article

VL - 173

SP - 2855

EP - 2865

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -